Claritin for OTC allergy relief
This article was originally published in The Tan Sheet
Executive SummaryAlmost half (42%) of allergy-sufferers surveyed intend to purchase Schering-Plough's Claritin (loratadine) when it is available OTC, according to study by market research firm Ipsos PharmTrends. Results indicate Claritin "would displace all other OTC and Rx drugs as the preferred remedy," since current OTC category leader, Pfizer Consumer Healthcare's Benadryl, was used by about 32% of allergy sufferers interviewed. Ipsos predicts S-P's successful DTC brand awareness campaign will "carry into the OTC arena, placing incremental pressure" on competing drugs; firm found 91% of allergy sufferers have heard of Claritin. Survey involved random sample of 1,000 adults nationwide...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.